Seeing a share price double is one of those rare moments that reminds investors why they bother putting capital at risk in the first place.
Watching a stock climb 100%, 200%, or even more in a relatively short period feels incredible — especially when it's sitting in your own portfolio.
That said, the reality is that most enduring wealth on the share market is built through patience and long-term ownership of quality businesses. Short-term share price surges are unpredictable and often volatile. However, when it does happen, it is usually tied to powerful underlying themes and/or a sharp improvement in fundamentals.
So far in 2025, a handful of ASX-listed companies with market capitalisations above $1 billion — well clear of penny stocks or microcaps — have delivered multibagger returns. Here are three of the standouts.
Image source: Getty Images
1. Electro Optic Systems Holdings Ltd (ASX: EOS)
12-month gain: +617%
Electro Optic Systems designs and manufactures advanced defence and space systems, including remote weapon stations, counter-drone technologies, and satellite communications equipment. Its products are used by military and security customers globally, placing the company squarely in the crosshairs of rising defence spending.
The company's share price surge reflects a dramatic shift in market perception. Strong contract momentum, expanding order books, and improving operational execution have convinced investors that EOS is transitioning from a volatile defence contractor into a more reliable, scalable supplier aligned with long-term geopolitical tailwinds.
Heightened global security concerns, particularly across Europe and allied nations, have put counter-drone and defence capabilities in sharp focus. That has driven renewed investor confidence and a significant re-rating of earnings expectations.
2. 4DMedical Ltd (ASX: 4DX)
12-month gain: +547.8%
4DMedical sits at the intersection of healthcare and advanced imaging technology. The company's proprietary lung imaging platform allows clinicians to assess respiratory function with far greater precision than traditional methods, helping diagnose and manage conditions such as COPD, asthma, and post-viral lung damage.
The explosive share price move in 2025 has been driven by accelerating commercial traction, particularly in the US healthcare market. Regulatory progress, reimbursement milestones, and growing clinical adoption have shifted the company from "promising technology" to genuine commercial contender.
Investors have responded to clearer pathways to revenue scalability, recurring usage, and broader clinical acceptance. As confidence in the business model has improved, so too has the valuation investors are willing to place on future growth.
3. DroneShield Ltd (ASX: DRO)
12-month gain: +356.9%
DroneShield develops counter-drone detection and mitigation systems used by military, government, and critical infrastructure operators. As drone warfare and security threats have become increasingly prominent, demand for DroneShield's technology has surged.
The company has delivered a steady stream of contract wins across Europe, the Americas, and allied defence networks, including several record-breaking orders. Investment in manufacturing capacity and R&D has further reinforced the market's belief that DroneShield is positioning itself as a global leader in a fast-growing niche.
Importantly, the share price gains haven't followed a straight line. While strong contract wins and expanding demand have underpinned the longer-term move, DroneShield shares have also been volatile, with periods of sharp pullbacks and increased scrutiny around management actions and communication. As with many fast-rising growth stocks, investor sentiment has shifted quickly at times, reinforcing the importance of patience and risk awareness.
A Foolish word on multibaggers
Stories like these are undeniably inspiring. But it's worth remembering that rapid gains often come with heightened volatility. Big winners can pull back sharply, and past performance alone is never a guarantee of future returns.
For many investors, the most practical takeaway isn't to chase yesterday's multibagger — it's to focus on owning quality businesses early, staying diversified, and giving time for compounding to do its work. Occasionally, that discipline is rewarded with an outsized winner along the way.
And when it happens, it's a reminder that the ASX is still capable of producing world-class growth stories.
